Prize fight in Paris: Al­ny­lam and Io­n­is slug it out over PhI­II da­ta in prepa­ra­tion for a block­buster show­down

This morn­ing Al­ny­lam $AL­NY rolled out a bat­tery of stel­lar Phase III da­ta on their block­buster con­tender patisir­an, which promis­es to go on to be­come the com­pa­ny’s first ap­proved and mar­ket­ed drug af­ter 15 long years of RNAi dis­cov­ery and de­vel­op­ment work. And as of now, it looks like they’ll be go­ing head-to-head with the an­ti­sense ex­perts at Io­n­is $IONS, the un­der­dogs in what promis­es to be a long run­ning fight for a small group of pa­tients suf­fer­ing from rare cas­es of hered­i­tary AT­TR (hAT­TR) amy­loi­do­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER